

RECEIVED

APR 28 2000

TECH CENTER 1600/2000 PATENT

1633
#9
5/1/00
RJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Daniel B. Drachman

Serial No. 09/205,096

Filed: December 3, 1998



) Group Art Unit: 1633

) Examiner: E. Sorbello

) Atty. Docket No. 01107.77737

FOR: **TARGETING ANTIGEN-SPECIFIC T CELLS FOR SPECIFIC IMMUNOTHERAPY
OF AUTOIMMUNE DISEASE**

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 28, 2000, applicant elects the following two species:

Fas ligand, and

Vaccinia Virus


Applicant understands that upon allowance of a generic claim, it is entitled to consideration of additional species which are actually or virtually dependent on an allowed generic claim.

The following claims are readable on the elected species: 1-3, 6-8, 13, 15, 16-18, 20-21, 23-27, 29-30, 32-34 and 36-40.

If any fee is due, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: April 25, 2000

By: 
Sarah A. Kagan
Registration No. 32,141

Banner & Witcoff, Ltd.
1001 G Street, N.W., Eleventh Floor
Washington, D.C. 20001-4597
(202) 508-9100

SAK/ama